Entering text into the input field will update the search result below

InflaRx stock rises 14% as vilobelimab gets FDA fast track status for skin disorder

Jul. 06, 2022 7:47 AM ETInflaRx N.V. (IFRX) StockBy: Ravikash, SA News Editor

Headquarters of US Food and Drug Administration (FDA)


  • The U.S. Food and Drug Administration (FDA) granted fast track designation to InflaRx's (NASDAQ:IFRX) vilobelimab to treat ulcerative pyoderma gangrenosum (PG).
  • PG is a rare disorder which causes large, painful ulcers to develop on the skin, often on the legs.
  • The company had had submitted a request for a fast track designation after positive data in a phase 2a trial in PG, Germany-based InflaRx said in a July 6 press release.
  • Vilobelimab has already received orphan drug status for PG in the U.S. and EU.
  • IFRX +14.08% to $1.62 premarket July 6

Recommended For You


Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

About IFRX

SymbolLast Price% Chg
Market Cap
Yield (TTM)
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
InflaRx N.V.
Theratechnologies Inc.
Shattuck Labs, Inc.
BriaCell Therapeutics Corp.
MediciNova, Inc.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.